SPDR Dow Jones REIT ETF |
SPDR S&P Biotech ETF |
SPDR S&P Dividend ETF |
Portfolio Statistics (Unaudited) | |
|
1 |
|
2 |
|
3 |
Schedules of Investments (Unaudited) | |
|
4 |
|
8 |
|
15 |
|
22 |
|
27 |
|
30 |
|
41 |
Description | % of Net Assets | ||
Prologis, Inc. REIT | 9.5% | ||
Digital Realty Trust, Inc. REIT | 5.1 | ||
Public Storage REIT | 4.6 | ||
Simon Property Group, Inc. REIT | 3.6 | ||
Welltower, Inc. REIT | 3.5 | ||
AvalonBay Communities, Inc. REIT | 2.9 | ||
Alexandria Real Estate Equities, Inc. REIT | 2.9 | ||
Realty Income Corp. REIT | 2.8 | ||
Equity Residential REIT | 2.6 | ||
Ventas, Inc. REIT | 2.4 | ||
TOTAL | 39.9% |
% of Net Assets | |||
Residential REITS | 21.0% | ||
Industrial REITS | 17.1 | ||
Specialized REITS | 14.7 | ||
Retail REITS | 13.6 | ||
Office REITS | 12.0 | ||
Health Care REITS | 11.6 | ||
Diversified REITS | 5.1 | ||
Hotel & Resort REITS | 4.4 | ||
Short-Term Investments | 1.4 | ||
Liabilities in Excess of Other Assets | (0.9) | ||
TOTAL | 100.0% |
Description | % of Net Assets | ||
Alexion Pharmaceuticals, Inc. | 1.2% | ||
Agios Pharmaceuticals, Inc. | 1.2 | ||
Sage Therapeutics, Inc. | 1.1 | ||
Ionis Pharmaceuticals, Inc. | 1.1 | ||
TG Therapeutics, Inc. | 1.1 | ||
Kodiak Sciences, Inc. | 1.1 | ||
Bridgebio Pharma, Inc. | 1.1 | ||
Apellis Pharmaceuticals, Inc. | 1.0 | ||
Editas Medicine, Inc. | 1.0 | ||
Arena Pharmaceuticals, Inc. | 1.0 | ||
TOTAL | 10.9% |
% of Net Assets | |||||
Biotechnology | 100.0% | ||||
Health Care Equipment & Supplies | 0.0* | ||||
Short Term Investments | 15.7 | ||||
Liabilities in Excess of Other Assets | (15.7) | ||||
TOTAL | 100.0% | ||||
* | Amount shown represents less than 0.05% of net assets. |
Description | % of Net Assets | ||
Exxon Mobil Corp. | 3.7% | ||
Chevron Corp. | 2.5 | ||
People's United Financial, Inc. | 2.4 | ||
AT&T, Inc. | 2.3 | ||
National Retail Properties, Inc. REIT | 2.1 | ||
AbbVie, Inc. | 2.1 | ||
Federal Realty Investment Trust REIT | 2.0 | ||
International Business Machines Corp. | 1.8 | ||
Franklin Resources, Inc. | 1.7 | ||
Old Republic International Corp. | 1.7 | ||
TOTAL | 22.3% |
% of Net Assets | |||||
Financials | 18.7% | ||||
Industrials | 17.3 | ||||
Consumer Staples | 12.1 | ||||
Utilities | 12.1 | ||||
Materials | 8.4 | ||||
Real Estate | 7.0 | ||||
Energy | 6.2 | ||||
Health Care | 6.0 | ||||
Consumer Discretionary | 5.7 | ||||
Communication Services | 3.6 | ||||
Information Technology | 2.7 | ||||
Short-Term Investments | 0.2 | ||||
Other Assets in Excess of Liabilities | 0.0 * | ||||
TOTAL | 100.0% | ||||
* | Amount shown represents less than 0.05% of net assets. |
Security Description | Shares | Value | ||||
COMMON STOCKS — 99.5% | ||||||
EQUITY REAL ESTATE INVESTMENT TRUSTS (REITS) — 99.5% | ||||||
Acadia Realty Trust REIT
|
155,419 | $ 2,205,396 | ||||
Agree Realty Corp. REIT (a)
|
98,648 | 6,567,984 | ||||
Alexandria Real Estate Equities, Inc. REIT
|
220,535 | 39,303,748 | ||||
American Assets Trust, Inc. REIT
|
90,604 | 2,616,644 | ||||
American Campus Communities, Inc. REIT
|
244,958 | 10,476,854 | ||||
American Homes 4 Rent Class A REIT
|
477,412 | 14,322,360 | ||||
Americold Realty Trust REIT
|
364,540 | 13,608,278 | ||||
Apartment Income REIT Corp. (b)
|
265,014 | 10,179,188 | ||||
Apartment Investment & Management Co. Class A
REIT
|
270,214 | 1,426,730 | ||||
Apple Hospitality REIT, Inc.
|
370,653 | 4,785,130 | ||||
AvalonBay Communities, Inc. REIT
|
248,561 | 39,876,641 | ||||
Boston Properties, Inc. REIT
|
251,929 | 23,814,848 | ||||
Brandywine Realty Trust REIT
|
301,319 | 3,588,709 | ||||
Brixmor Property Group, Inc. REIT
|
527,895 | 8,736,662 | ||||
Camden Property Trust REIT
|
173,248 | 17,310,940 | ||||
CareTrust REIT, Inc.
|
169,146 | 3,751,658 | ||||
Centerspace REIT
|
23,350 | 1,649,444 | ||||
Chatham Lodging Trust REIT
|
84,361 | 911,099 | ||||
City Office REIT, Inc.
|
76,661 | 748,978 | ||||
Columbia Property Trust, Inc. REIT
|
201,985 | 2,896,465 | ||||
Community Healthcare Trust, Inc. REIT
|
38,876 | 1,831,448 | ||||
Corporate Office Properties Trust REIT
|
200,250 | 5,222,520 | ||||
Cousins Properties, Inc. REIT
|
264,823 | 8,871,571 | ||||
CubeSmart REIT
|
347,537 | 11,680,719 | ||||
DiamondRock Hospitality Co. REIT
|
352,124 | 2,905,023 | ||||
Digital Realty Trust, Inc. REIT
|
498,813 | 69,589,402 | ||||
Diversified Healthcare Trust REIT
|
434,529 | 1,790,260 | ||||
Douglas Emmett, Inc. REIT
|
293,878 | 8,575,360 | ||||
Duke Realty Corp. REIT
|
661,569 | 26,442,913 | ||||
Easterly Government Properties, Inc. REIT
|
144,804 | 3,279,811 | ||||
EastGroup Properties, Inc. REIT
|
70,395 | 9,718,734 | ||||
Empire State Realty Trust, Inc. Class A REIT
(a)
|
247,127 | 2,303,224 | ||||
EPR Properties REIT
|
131,877 | 4,286,003 | ||||
Equity Commonwealth REIT
|
216,783 | 5,913,840 | ||||
Equity LifeStyle Properties, Inc. REIT
|
301,479 | 19,101,709 | ||||
Equity Residential REIT
|
609,143 | 36,109,997 | ||||
Essential Properties Realty Trust, Inc.
REIT
|
185,328 | 3,928,954 | ||||
Essex Property Trust, Inc. REIT
|
115,963 | 27,531,936 | ||||
Extra Space Storage, Inc. REIT
|
229,879 | 26,633,781 | ||||
Federal Realty Investment Trust REIT
|
122,499 | 10,427,115 |
Security Description | Shares | Value | |||
First Industrial Realty Trust, Inc. REIT
|
230,048 | $ 9,691,922 | |||
Four Corners Property Trust, Inc. REIT
|
130,983 | 3,899,364 | |||
Franklin Street Properties Corp. REIT
|
171,264 | 748,424 | |||
Front Yard Residential Corp. REIT
|
88,402 | 1,432,112 | |||
Getty Realty Corp. REIT
|
64,073 | 1,764,570 | |||
Global Net Lease, Inc. REIT
|
158,558 | 2,717,684 | |||
Healthcare Realty Trust, Inc. REIT
|
242,632 | 7,181,907 | |||
Healthcare Trust of America, Inc. Class A
REIT
|
389,110 | 10,716,089 | |||
Healthpeak Properties, Inc. REIT
|
957,604 | 28,948,369 | |||
Hersha Hospitality Trust REIT
|
64,702 | 510,499 | |||
Highwoods Properties, Inc. REIT
|
185,283 | 7,342,765 | |||
Host Hotels & Resorts, Inc. REIT
|
1,254,959 | 18,360,050 | |||
Hudson Pacific Properties, Inc. REIT
|
271,444 | 6,520,085 | |||
Independence Realty Trust, Inc. REIT
|
168,100 | 2,257,583 | |||
Industrial Logistics Properties Trust REIT
|
115,731 | 2,695,375 | |||
Innovative Industrial Properties, Inc. REIT
(a)
|
39,324 | 7,201,404 | |||
Invitation Homes, Inc. REIT
|
997,029 | 29,611,761 | |||
JBG SMITH Properties REIT
|
198,495 | 6,206,939 | |||
Kilroy Realty Corp. REIT
|
186,683 | 10,715,604 | |||
Kimco Realty Corp. REIT
|
769,812 | 11,554,878 | |||
Kite Realty Group Trust REIT
|
151,725 | 2,269,806 | |||
Lexington Realty Trust REIT
|
494,265 | 5,249,094 | |||
Life Storage, Inc. REIT
|
86,548 | 10,332,966 | |||
LTC Properties, Inc. REIT
|
69,561 | 2,706,619 | |||
Macerich Co. REIT (a)
|
201,712 | 2,152,267 | |||
Mack-Cali Realty Corp. REIT
|
152,735 | 1,903,078 | |||
Mid-America Apartment Communities, Inc.
REIT
|
203,454 | 25,775,587 | |||
Monmouth Real Estate Investment Corp. REIT
|
173,098 | 2,998,057 | |||
National Health Investors, Inc. REIT
|
79,818 | 5,521,011 | |||
National Retail Properties, Inc. REIT
|
309,134 | 12,649,763 | |||
National Storage Affiliates Trust REIT
|
111,269 | 4,009,022 | |||
NexPoint Residential Trust, Inc. REIT
|
39,943 | 1,689,988 | |||
Office Properties Income Trust REIT
|
87,796 | 1,994,725 | |||
Omega Healthcare Investors, Inc. REIT
|
403,937 | 14,670,992 | |||
Paramount Group, Inc. REIT
|
296,511 | 2,680,459 | |||
Park Hotels & Resorts, Inc. REIT
|
420,175 | 7,206,001 | |||
Pebblebrook Hotel Trust REIT
|
233,734 | 4,394,199 | |||
Piedmont Office Realty Trust, Inc. Class A
REIT
|
222,597 | 3,612,749 | |||
Prologis, Inc. REIT
|
1,316,037 | 131,156,247 | |||
PS Business Parks, Inc. REIT
|
35,497 | 4,716,486 | |||
Public Storage REIT
|
270,846 | 62,546,467 | |||
QTS Realty Trust, Inc. Class A REIT (a)
|
114,667 | 7,095,594 |
Security Description | Shares | Value | ||||
Realty Income Corp. REIT
|
625,079 | $ 38,861,161 | ||||
Regency Centers Corp. REIT
|
280,830 | 12,803,040 | ||||
Retail Opportunity Investments Corp. REIT
|
212,835 | 2,849,861 | ||||
Retail Properties of America, Inc. Class A
REIT
|
378,341 | 3,238,599 | ||||
Rexford Industrial Realty, Inc. REIT
|
232,365 | 11,411,445 | ||||
RLJ Lodging Trust REIT
|
291,624 | 4,126,480 | ||||
RPT Realty REIT
|
144,715 | 1,251,785 | ||||
Ryman Hospitality Properties, Inc. REIT
|
98,080 | 6,645,901 | ||||
Seritage Growth Properties Class A REIT (a)
(b)
|
66,123 | 970,686 | ||||
Service Properties Trust REIT
|
291,109 | 3,344,842 | ||||
Simon Property Group, Inc. REIT
|
583,874 | 49,792,775 | ||||
SITE Centers Corp. REIT
|
265,942 | 2,691,333 | ||||
SL Green Realty Corp. REIT (a)
|
129,466 | 7,713,584 | ||||
Spirit Realty Capital, Inc. REIT
|
203,467 | 8,173,269 | ||||
STAG Industrial, Inc. REIT
|
266,067 | 8,333,218 | ||||
STORE Capital Corp. REIT
|
420,611 | 14,292,362 | ||||
Summit Hotel Properties, Inc. REIT
|
189,694 | 1,709,143 | ||||
Sun Communities, Inc. REIT
|
191,363 | 29,077,608 | ||||
Sunstone Hotel Investors, Inc. REIT
|
385,084 | 4,363,002 | ||||
Tanger Factory Outlet Centers, Inc. REIT
(a)
|
167,836 | 1,671,647 | ||||
Terreno Realty Corp. REIT
|
121,930 | 7,134,124 | ||||
UDR, Inc. REIT
|
523,868 | 20,132,247 | ||||
Universal Health Realty Income Trust REIT
|
23,104 | 1,484,894 | ||||
Urban Edge Properties REIT
|
197,917 | 2,561,046 | ||||
Ventas, Inc. REIT
|
666,231 | 32,671,968 | ||||
VEREIT, Inc.
|
388,561 | 14,683,720 | ||||
Vornado Realty Trust REIT
|
279,149 | 10,423,424 | ||||
Washington Prime Group, Inc. REIT (a)
|
37,387 | 243,391 | ||||
Washington Real Estate Investment Trust
|
145,433 | 3,145,716 | ||||
Weingarten Realty Investors REIT
|
215,088 | 4,660,957 | ||||
Welltower, Inc. REIT
|
743,084 | 48,018,088 | ||||
WP Carey, Inc. REIT
|
312,046 | 22,024,207 | ||||
Xenia Hotels & Resorts, Inc. REIT
|
200,747 | 3,051,354 | ||||
TOTAL COMMON STOCKS (Cost
$1,515,939,143)
|
1,365,887,514 | |||||
SHORT-TERM INVESTMENTS — 1.4% | ||||||
State Street Institutional Liquid Reserves Fund,
Premier Class 0.10% (c) (d)
|
2,183,183 | 2,183,620 |
Security Description | Shares | Value | ||||
State Street Navigator Securities Lending
Portfolio II (e) (f)
|
17,113,729 | $ 17,113,729 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost
$19,297,349)
|
19,297,349 | |||||
TOTAL INVESTMENTS — 100.9% (Cost
$1,535,236,492)
|
1,385,184,863 | |||||
LIABILITIES IN EXCESS OF OTHER ASSETS — (0.9)%
|
(12,366,061) | |||||
NET ASSETS — 100.0%
|
$ 1,372,818,802 |
(a) | All or a portion of the shares of the security are on loan at December 31, 2020. |
(b) | Non-income producing security. |
(c) | The Fund invested in certain money market funds managed by SSGA Funds Management, Inc. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(d) | The rate shown is the annualized seven-day yield at December 31, 2020. |
(e) | The Fund invested in an affiliated entity. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(f) | Investment of cash collateral for securities loaned. |
REIT | Real Estate Investment Trust |
Description | Level
1 – Quoted Prices |
Level
2 – Other Significant Observable Inputs |
Level
3 – Significant Unobservable Inputs |
Total | ||||
ASSETS: | ||||||||
INVESTMENTS: | ||||||||
Common Stocks
|
$1,365,887,514 | $— | $— | $1,365,887,514 | ||||
Short-Term Investments
|
19,297,349 | — | — | 19,297,349 | ||||
TOTAL INVESTMENTS
|
$1,385,184,863 | $— | $— | $1,385,184,863 |
Number
of Shares Held at 6/30/20 |
Value
at 6/30/20 |
Cost
of Purchases |
Proceeds
from Shares Sold |
Realized
Gain (Loss) |
Change
in Unrealized Appreciation/ Depreciation |
Number
of Shares Held at 12/31/20 |
Value
at 12/31/20 |
Dividend
Income | |||||||||
State Street Institutional Liquid Reserves Fund,
Premier Class
|
4,097,975 | $ 4,099,614 | $ 49,338,743 | $ 51,253,652 | $(1,085) | $— | 2,183,183 | $ 2,183,620 | $ 943 | ||||||||
State Street Navigator Securities Lending
Portfolio II
|
9,665,286 | 9,665,286 | 100,720,449 | 93,272,006 | — | — | 17,113,729 | 17,113,729 | 113,401 | ||||||||
Total
|
$13,764,900 | $150,059,192 | $144,525,658 | $(1,085) | $— | $19,297,349 | $114,344 |
Security Description | Shares | Value | |||
COMMON STOCKS — 100.0% | |||||
BIOTECHNOLOGY — 100.0% | |||||
AbbVie, Inc.
|
588,432 | $ 63,050,489 | |||
ACADIA Pharmaceuticals, Inc. (a)
|
1,220,828 | 65,265,465 | |||
Acceleron Pharma, Inc. (a) (b)
|
503,520 | 64,420,349 | |||
Achillion Pharmaceuticals, Inc. (a)
(b)
|
51,865 | 75,464 | |||
Adverum Biotechnologies, Inc. (a) (b)
|
2,529,837 | 27,423,433 | |||
Agenus, Inc. (a) (b)
|
7,323,587 | 23,289,007 | |||
Agios Pharmaceuticals, Inc. (a) (b)
|
1,856,214 | 80,429,753 | |||
Akebia Therapeutics, Inc. (a) (b)
(c)
|
19,737,122 | 55,263,942 | |||
Akero Therapeutics, Inc. (a) (b)
|
592,212 | 15,279,070 | |||
Albireo Pharma, Inc. (a) (b)
|
507,025 | 19,018,508 | |||
Alector, Inc. (a) (b)
|
2,155,335 | 32,610,219 | |||
Alexion Pharmaceuticals, Inc. (a)
|
517,250 | 80,815,140 | |||
Alkermes PLC (a) (b)
|
2,937,759 | 58,608,292 | |||
Allakos, Inc. (a) (b)
|
422,293 | 59,121,020 | |||
Allogene Therapeutics, Inc. (a) (b)
|
2,282,103 | 57,600,280 | |||
Allovir, Inc. (a)
|
454,682 | 17,477,976 | |||
Alnylam Pharmaceuticals, Inc. (a)
|
482,631 | 62,727,551 | |||
ALX Oncology Holdings, Inc. (a)
|
214,737 | 18,510,329 | |||
Amgen, Inc.
|
275,202 | 63,274,444 | |||
Amicus Therapeutics, Inc. (a)
|
2,831,442 | 65,377,996 | |||
AnaptysBio, Inc. (a) (b)
|
778,765 | 16,743,448 | |||
Anika Therapeutics, Inc. (a) (b)
|
313,456 | 14,187,019 | |||
Apellis Pharmaceuticals, Inc. (a) (b)
|
1,259,171 | 72,024,581 | |||
Applied Molecular Transport, Inc. (a)
(b)
|
323,297 | 9,947,849 | |||
Arcturus Therapeutics Holdings, Inc. (a)
(b)
|
590,246 | 25,604,871 | |||
Arcus Biosciences, Inc. (a) (b)
|
984,042 | 25,545,730 | |||
Arcutis Biotherapeutics, Inc. (a) (b)
|
507,625 | 14,279,491 | |||
Ardelyx, Inc. (a) (b)
|
1,094,534 | 7,081,635 | |||
Arena Pharmaceuticals, Inc. (a) (b)
|
904,451 | 69,488,970 | |||
Arrowhead Pharmaceuticals, Inc. (a)
(b)
|
844,894 | 64,828,717 | |||
Atara Biotherapeutics, Inc. (a)
|
1,446,897 | 28,402,588 | |||
Athenex, Inc. (a) (b)
|
2,018,212 | 22,321,425 | |||
Athersys, Inc. (a) (b)
|
5,984,093 | 10,472,163 | |||
Atreca, Inc. Class A (a) (b)
|
508,452 | 8,211,500 | |||
Avidity Biosciences, Inc. (a) (b)
|
398,174 | 10,161,400 | |||
Avita Therapeutics, Inc. (a) (b)
|
281,352 | 5,227,520 | |||
Avrobio, Inc. (a) (b)
|
706,517 | 9,848,847 | |||
Beam Therapeutics, Inc. (a) (b)
|
726,680 | 59,326,155 | |||
BioCryst Pharmaceuticals, Inc. (a)
|
7,541,704 | 56,185,695 | |||
Biogen, Inc. (a) (b)
|
259,209 | 63,469,916 |
Security Description | Shares | Value | |||
Biohaven Pharmaceutical Holding Co., Ltd.
(a)
|
716,939 | $ 61,448,842 | |||
BioMarin Pharmaceutical, Inc. (a) (b)
|
787,292 | 69,037,635 | |||
Bioxcel Therapeutics, Inc. (a) (b)
(c)
|
1,451,563 | 67,062,211 | |||
Black Diamond Therapeutics, Inc. (a)
(b)
|
520,988 | 16,697,665 | |||
Bluebird Bio, Inc. (a) (b)
|
1,473,869 | 63,774,312 | |||
Blueprint Medicines Corp. (a)
|
545,602 | 61,189,264 | |||
Bridgebio Pharma, Inc. (a) (b)
|
1,019,997 | 72,531,987 | |||
Cardiff Oncology, Inc. (a) (b)
(c)
|
2,537,816 | 45,655,310 | |||
CareDx, Inc. (a) (b)
|
907,655 | 65,759,605 | |||
Catalyst Pharmaceuticals, Inc. (a)
(b)
|
4,066,916 | 13,583,499 | |||
Celldex Therapeutics, Inc. (a) (b)
|
1,731,176 | 30,330,204 | |||
CEL-SCI Corp. (a) (b)
|
1,336,527 | 15,583,905 | |||
ChemoCentryx, Inc. (a) (b)
|
1,030,725 | 63,822,492 | |||
Clovis Oncology, Inc. (a) (b)
(c)
|
12,902,198 | 61,930,550 | |||
Coherus Biosciences, Inc. (a) (b)
|
2,841,130 | 49,378,839 | |||
Constellation Pharmaceuticals, Inc. (a)
(b)
|
1,094,631 | 31,525,373 | |||
Cortexyme, Inc. (a) (b)
|
537,260 | 14,925,083 | |||
Cue Biopharma, Inc. (a) (b)
|
883,121 | 11,047,844 | |||
Cytokinetics, Inc. (a) (b)
|
2,666,616 | 55,412,280 | |||
CytomX Therapeutics, Inc. (a) (b)
|
1,109,790 | 7,269,125 | |||
Deciphera Pharmaceuticals, Inc. (a)
(b)
|
1,098,150 | 62,671,420 | |||
Denali Therapeutics, Inc. (a) (b)
|
782,007 | 65,500,906 | |||
Dicerna Pharmaceuticals, Inc. (a) (b)
|
1,508,612 | 33,234,722 | |||
Dynavax Technologies Corp. (a) (b)
(c)
|
8,873,658 | 39,487,778 | |||
Eagle Pharmaceuticals, Inc. (a) (b)
|
467,792 | 21,785,073 | |||
Editas Medicine, Inc. (a) (b)
|
1,010,564 | 70,850,642 | |||
Emergent BioSolutions, Inc. (a) (b)
|
747,818 | 67,004,493 | |||
Enanta Pharmaceuticals, Inc. (a) (b)
|
552,337 | 23,253,388 | |||
Epizyme, Inc. (a) (b)
|
2,610,005 | 28,344,654 | |||
Esperion Therapeutics, Inc. (a) (b)
(c)
|
2,004,475 | 52,116,350 | |||
Exact Sciences Corp. (a) (b)
|
483,193 | 64,018,241 | |||
Exelixis, Inc. (a) (b)
|
3,149,259 | 63,205,628 | |||
Fate Therapeutics, Inc. (a)
|
660,513 | 60,060,447 | |||
FibroGen, Inc. (a) (b)
|
1,525,887 | 56,595,149 | |||
Five Prime Therapeutics, Inc. (a)
|
423,409 | 7,202,187 | |||
Flexion Therapeutics, Inc. (a) (b)
|
1,637,876 | 18,901,089 | |||
Forma Therapeutics Holdings, Inc. (a)
|
568,104 | 19,826,830 | |||
Frequency Therapeutics, Inc. (a) (b)
|
333,577 | 11,761,925 | |||
G1 Therapeutics, Inc. (a) (b)
(c)
|
1,929,978 | 34,720,304 | |||
Generation Bio Co. (a) (b)
|
326,359 | 9,252,278 | |||
Geron Corp. (a) (b)
|
8,213,902 | 13,060,104 | |||
Gilead Sciences, Inc.
|
1,029,861 | 59,999,702 |
Security Description | Shares | Value | |||
Global Blood Therapeutics, Inc. (a)
(b)
|
1,542,505 | $ 66,805,892 | |||
Gossamer Bio, Inc. (a) (b)
|
1,679,170 | 16,237,574 | |||
Halozyme Therapeutics, Inc. (a) (b)
|
1,524,364 | 65,105,586 | |||
Heron Therapeutics, Inc. (a) (b)
|
2,273,719 | 48,123,263 | |||
IGM Biosciences, Inc. (a) (b)
|
420,507 | 37,126,563 | |||
ImmunoGen, Inc. (a) (b)
|
5,337,603 | 34,427,539 | |||
Immunovant, Inc. (a) (b)
|
1,138,919 | 52,606,669 | |||
Incyte Corp. (a) (b)
|
769,751 | 66,952,942 | |||
Inovio Pharmaceuticals, Inc. (a) (b)
|
5,657,898 | 50,072,397 | |||
Insmed, Inc. (a) (b)
|
1,568,683 | 52,221,457 | |||
Intellia Therapeutics, Inc. (a)
|
1,174,909 | 63,915,050 | |||
Intercept Pharmaceuticals, Inc.
(a) (b) (c)
|
2,037,658 | 50,330,153 | |||
Invitae Corp. (a) (b)
|
1,105,590 | 46,224,718 | |||
Ionis Pharmaceuticals, Inc. (a) (b)
|
1,365,941 | 77,230,304 | |||
Iovance Biotherapeutics, Inc. (a) (b)
|
1,252,723 | 58,126,347 | |||
Ironwood Pharmaceuticals, Inc. (a)
(b)
|
4,445,509 | 50,634,348 | |||
IVERIC bio, Inc. (a)
|
2,019,746 | 13,956,445 | |||
Kadmon Holdings, Inc. (a) (b)
|
6,604,593 | 27,409,061 | |||
Karuna Therapeutics, Inc. (a) (b)
|
472,151 | 47,965,820 | |||
Karyopharm Therapeutics, Inc. (a) (b)
(c)
|
3,956,042 | 61,239,530 | |||
Keros Therapeutics, Inc. (a) (b)
|
206,745 | 14,583,792 | |||
Kiniksa Pharmaceuticals Ltd. Class A (a)
(b)
|
1,125,454 | 19,886,772 | |||
Kodiak Sciences, Inc. (a) (b)
|
497,288 | 73,056,580 | |||
Krystal Biotech, Inc. (a) (b)
|
288,248 | 17,294,880 | |||
Kura Oncology, Inc. (a) (b)
|
1,503,428 | 49,101,958 | |||
Ligand Pharmaceuticals, Inc. (a) (b)
|
674,033 | 67,032,582 | |||
MacroGenics, Inc. (a)
|
1,508,911 | 34,493,705 | |||
Madrigal Pharmaceuticals, Inc. (a)
(b)
|
468,084 | 52,036,898 | |||
MannKind Corp. (a) (b)
|
5,072,559 | 15,877,110 | |||
Mersana Therapeutics, Inc. (a) (b)
|
2,086,179 | 55,513,223 | |||
Mirati Therapeutics, Inc. (a)
|
262,577 | 57,672,412 | |||
Moderna, Inc. (a)
|
398,723 | 41,654,592 | |||
Myriad Genetics, Inc. (a) (b)
|
1,374,756 | 27,185,800 | |||
Natera, Inc. (a)
|
648,134 | 64,502,296 | |||
Neoleukin Therapeutics, Inc. (a) (b)
|
627,101 | 8,842,124 | |||
Neurocrine Biosciences, Inc. (a) (b)
|
693,671 | 66,488,365 | |||
Nkarta, Inc. (a)
|
244,272 | 15,015,400 | |||
Novavax, Inc. (a) (b)
|
501,111 | 55,878,888 | |||
Nurix Therapeutics, Inc. (a)
|
256,235 | 8,425,007 | |||
OPKO Health, Inc. (a) (b)
|
14,062,019 | 55,544,975 | |||
Precigen, Inc. (a) (b)
|
1,660,210 | 16,934,142 | |||
Precision BioSciences, Inc. (a) (b)
|
1,672,859 | 13,951,644 |
Security Description | Shares | Value | |||
Protagonist Therapeutics, Inc. (a)
(b)
|
931,333 | $ 18,775,673 | |||
PTC Therapeutics, Inc. (a) (b)
|
963,030 | 58,773,721 | |||
Puma Biotechnology, Inc. (a) (b)
|
1,626,482 | 16,687,705 | |||
Radius Health, Inc. (a) (b)
|
1,428,868 | 25,519,582 | |||
Regeneron Pharmaceuticals, Inc. (a)
|
130,408 | 63,001,409 | |||
REGENXBIO, Inc. (a) (b)
|
826,264 | 37,479,335 | |||
Relay Therapeutics, Inc. (a)
|
736,342 | 30,602,374 | |||
Replimenu Group, Inc. (a)
|
1,137,708 | 43,403,560 | |||
REVOLUTION Medicines, Inc. (a) (b)
|
1,077,158 | 42,644,685 | |||
Rhythm Pharmaceuticals, Inc. (a) (b)
|
656,403 | 19,514,861 | |||
Rigel Pharmaceuticals, Inc. (a) (b)
|
5,978,320 | 20,924,120 | |||
Rocket Pharmaceuticals, Inc. (a) (b)
|
467,887 | 25,658,923 | |||
Sage Therapeutics, Inc. (a) (b)
|
906,389 | 78,411,712 | |||
Sangamo Therapeutics, Inc. (a) (b)
|
4,018,225 | 62,704,401 | |||
Sarepta Therapeutics, Inc. (a) (b)
|
374,141 | 63,787,299 | |||
Scholar Rock Holding Corp. (a)
|
226,891 | 11,011,020 | |||
Seagen, Inc. (a)
|
327,312 | 57,325,424 | |||
Seres Therapeutics, Inc. (a) (b)
|
2,570,869 | 62,986,290 | |||
Sorrento Therapeutics, Inc. (a) (b)
|
7,951,266 | 54,267,390 | |||
Spectrum Pharmaceuticals, Inc. (a)
(b)
|
6,209,448 | 21,174,218 | |||
SpringWorks Therapeutics, Inc. (a)
(b)
|
620,034 | 44,964,866 | |||
Stoke Therapeutics, Inc. (a) (b)
|
203,783 | 12,620,281 | |||
Syndax Pharmaceuticals, Inc. (a) (b)
|
1,196,433 | 26,608,670 | |||
TCR2 Therapeutics, Inc. (a) (b)
|
513,852 | 15,893,442 | |||
TG Therapeutics, Inc. (a) (b)
|
1,480,358 | 77,008,223 | |||
Translate Bio, Inc. (a) (b)
|
1,723,823 | 31,770,058 | |||
Travere Therapeutics, Inc. (a) (b)
|
736,370 | 20,069,764 | |||
Turning Point Therapeutics, Inc. (a)
|
527,603 | 64,288,426 | |||
Twist Bioscience Corp. (a) (b)
|
441,762 | 62,416,553 | |||
Ultragenyx Pharmaceutical, Inc. (a)
(b)
|
431,788 | 59,772,413 | |||
uniQure NV (a) (b)
|
979,888 | 35,403,353 | |||
United Therapeutics Corp. (a)
|
451,195 | 68,486,889 | |||
Vanda Pharmaceuticals, Inc. (a) (b)
|
1,385,985 | 18,211,842 | |||
Vaxart, Inc. (a) (b) (c)
|
8,410,678 | 48,024,971 | |||
Vaxcyte, Inc. (a) (b)
|
605,058 | 16,076,391 | |||
VBI Vaccines, Inc. (a) (b) (c)
|
19,030,494 | 52,333,859 | |||
Veracyte, Inc. (a) (b)
|
1,045,008 | 51,142,692 | |||
Vericel Corp. (a) (b)
|
1,272,573 | 39,297,054 | |||
Vertex Pharmaceuticals, Inc. (a)
|
279,126 | 65,968,639 | |||
Viela Bio, Inc. (a) (b)
|
440,090 | 15,830,037 | |||
Viking Therapeutics, Inc. (a) (b)
(c)
|
3,761,458 | 21,177,009 | |||
Vir Biotechnology, Inc. (a) (b)
|
1,947,566 | 52,155,817 |
Security Description | Shares | Value | |||
Xencor, Inc. (a) (b)
|
795,786 | $ 34,720,143 | |||
Y-mAbs Therapeutics, Inc. (a) (b)
|
363,333 | 17,988,617 | |||
Zentalis Pharmaceuticals, Inc. (a)
(b)
|
412,993 | 21,450,856 | |||
ZIOPHARM Oncology, Inc. (a) (b)
|
4,453,573 | 11,223,004 | |||
6,901,059,956 | |||||
HEALTH CARE EQUIPMENT — 0.0% (d) | |||||
LENSAR, Inc. (a)
|
2,385 | 17,291 | |||
TOTAL COMMON STOCKS (Cost
$7,114,386,091)
|
6,901,077,247 | ||||
SHORT-TERM INVESTMENTS — 15.7% | |||||
State Street Institutional Liquid Reserves Fund,
Premier Class 0.10% (e) (f)
|
1,207,088 | 1,207,330 | |||
State Street Navigator Securities Lending
Portfolio II (g) (h)
|
1,086,364,528 | 1,086,364,528 | |||
TOTAL SHORT-TERM INVESTMENTS (Cost
$1,087,571,858)
|
1,087,571,858 | ||||
TOTAL INVESTMENTS — 115.7% (Cost
$8,201,957,949)
|
7,988,649,105 | ||||
LIABILITIES IN EXCESS OF OTHER ASSETS —
(15.7)%
|
(1,085,314,562) | ||||
NET ASSETS — 100.0%
|
$ 6,903,334,543 |
(a) | Non-income producing security. |
(b) | All or a portion of the shares of the security are on loan at December 31, 2020. |
(c) | These securities are affiliated investments as a result of the Fund owning 5% or more of the entity’s outstanding shares. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(d) | Amount is less than 0.05% of net assets. |
(e) | The Fund invested in certain money market funds managed by SSGA Funds Management, Inc. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(f) | The rate shown is the annualized seven-day yield at December 31, 2020. |
(g) | The Portfolio invested in an affiliated entity. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(h) | Investment of cash collateral for securities loaned. |
Description | Level
1 – Quoted Prices |
Level
2 – Other Significant Observable Inputs |
Level
3 – Significant Unobservable Inputs |
Total | ||||
ASSETS: | ||||||||
INVESTMENTS: | ||||||||
Common Stocks
|
$6,901,001,783 | $75,464 | $— | $6,901,077,247 | ||||
Short-Term Investments
|
1,087,571,858 | — | — | 1,087,571,858 | ||||
TOTAL INVESTMENTS
|
$7,988,573,641 | $75,464 | $— | $7,988,649,105 |
Number
of Shares Held at 6/30/20 |
Value
at 6/30/20 |
Cost
of Purchases |
Proceeds
from Shares Sold |
Realized
Gain (Loss) |
Change
in Unrealized Appreciation/ Depreciation(a) |
Number
of Shares Held at 12/31/20 |
Value
at 12/31/20 |
Dividend
Income | |||||||||
Akebia Therapeutics, Inc.
|
2,380,450 | $ 32,326,511 | $ 84,181,968 | $ 33,400,150 | $ 1,965,550 | $ (29,809,937) | 19,737,122 | $ 55,263,942 | $ — | ||||||||
Arcturus Therapeutics Holdings, Inc.
|
— | — | 135,790,946 | 153,196,765 | 55,896,512 | —* | — | —* | — | ||||||||
BioCryst Pharmaceuticals, Inc.
|
12,358,764 | 58,889,511 | 90,705,864 | 141,808,658 | 41,519,559 | —* | — | —* | — | ||||||||
Bioxcel Therapeutics, Inc.
|
774,443 | 41,053,223 | 82,445,940 | 48,176,148 | 452,579 | (8,713,383) | 1,451,563 | 67,062,211 | — | ||||||||
Cardiff Oncology, Inc.
|
— | — | 60,028,728 | 5,504,935 | (136,250) | (8,732,233) | 2,537,816 | 45,655,310 | — | ||||||||
Catalyst Pharmaceuticals, Inc.
|
4,713,118 | 21,774,605 | 28,797,213 | 30,480,917 | (3,375,990) | —* | — | —* | — | ||||||||
CEL-SCI Corp.
|
1,887,669 | 28,164,022 | 26,681,012 | 35,331,210 | 554,649 | —* | — | —* | — | ||||||||
Clovis Oncology, Inc.
|
7,843,117 | 52,941,040 | 79,554,352 | 51,201,029 | (4,248,646) | (15,115,167) | 12,902,198 | 61,930,550 | — | ||||||||
Corbus Pharmaceuticals Holdings, Inc.
|
1,770,830 | 14,857,264 | 47,522,540 | 44,655,157 | (16,598,235) | —* | — | —* | — | ||||||||
Dynavax Technologies Corp.
|
3,263,799 | 28,949,897 | 86,264,288 | 55,889,769 | (5,817,660) | (14,018,978) | 8,873,658 | 39,487,778 | — | ||||||||
Esperion Therapeutics, Inc.
|
1,219,434 | 62,569,159 | 72,685,176 | 48,122,391 | (1,788,348) | (33,227,246) | 2,004,475 | 52,116,350 | — | ||||||||
G1 Therapeutics, Inc.
|
661,220 | 16,041,197 | 45,677,671 | 26,114,084 | (981,185) | 96,705 | 1,929,978 | 34,720,304 | — | ||||||||
Intercept Pharmaceuticals, Inc.
|
705,260 | 33,789,007 | 85,505,808 | 39,520,226 | (264,616) | (29,179,820) | 2,037,658 | 50,330,153 | — | ||||||||
Karyopharm Therapeutics, Inc.
|
3,174,804 | 60,130,788 | 76,087,222 | 63,910,459 | (4,997,597) | (6,070,424) | 3,956,042 | 61,239,530 | — | ||||||||
Puma Biotechnology, Inc.
|
2,718,389 | 28,352,797 | 33,850,875 | 46,223,453 | (4,004,668) | —* | — | —* | — | ||||||||
State Street Institutional Liquid Reserves Fund,
Premier Class
|
6,399,493 | 6,402,053 | 138,526,872 | 143,720,710 | (828) | (57) | 1,207,088 | 1,207,330 | 5,000 | ||||||||
State Street Navigator Securities Lending
Portfolio II
|
857,417,617 | 857,417,617 | 2,874,335,810 | 2,645,388,899 | — | — | 1,086,364,528 | 1,086,364,528 | 18,189,352 | ||||||||
Translate Bio, Inc.
|
890,020 | 15,949,158 | 105,748,925 | 120,164,296 | 31,458,442 | —* | — | —* | — | ||||||||
Vaxart, Inc.
|
— | — | 68,171,781 | 6,186,683 | (170,683) | (13,789,444) | 8,410,678 | 48,024,971 | — | ||||||||
VBI Vaccines, Inc.
|
— | — | 100,591,249 | 35,220,796 | 930,916 | (13,967,510) | 19,030,494 | 52,333,859 | — | ||||||||
Viking Therapeutics, Inc.
|
2,913,435 | 21,005,866 | 34,900,739 | 29,157,838 | (6,995,956) | 1,424,198 | 3,761,458 | 21,177,009 | — | ||||||||
Total
|
$1,380,613,715 | $4,358,054,979 | $3,803,374,573 | $ 83,397,545 | $(171,103,296) | $1,676,913,825 | $18,194,352 |
(a) | Does not include change in unrealized appreciation and depreciation from investments that are no longer affiliates at period ended December 31, 2020. |
* | As of December 31, 2020, no longer an affiliate. |
Security Description | Shares | Value | ||||
COMMON STOCKS — 99.8% | ||||||
AEROSPACE & DEFENSE — 2.2% | ||||||
General Dynamics Corp.
|
1,172,954 | $ 174,559,014 | ||||
Raytheon Technologies Corp.
|
2,740,072 | 195,942,549 | ||||
370,501,563 | ||||||
AIR FREIGHT & LOGISTICS — 0.9% | ||||||
C.H. Robinson Worldwide, Inc. (a)
|
1,030,969 | 96,777,060 | ||||
Expeditors International of Washington,
Inc.
|
626,582 | 59,594,214 | ||||
156,371,274 | ||||||
BANKS — 8.3% | ||||||
Bank OZK (a) (b)
|
6,545,861 | 204,689,073 | ||||
Commerce Bancshares, Inc. (a)
|
1,640,543 | 107,783,675 | ||||
Community Bank System, Inc. (a)
|
1,904,138 | 118,646,839 | ||||
Cullen/Frost Bankers, Inc. (a)
|
2,784,250 | 242,870,127 | ||||
People's United Financial, Inc. (b)
|
31,695,076 | 409,817,333 | ||||
Prosperity Bancshares, Inc. (a)
|
3,113,037 | 215,920,246 | ||||
United Bankshares, Inc. (a)
|
3,916,359 | 126,890,032 | ||||
1,426,617,325 | ||||||
BEVERAGES — 2.3% | ||||||
Brown-Forman Corp. Class B
|
645,970 | 51,309,397 | ||||
Coca-Cola Co.
|
3,413,965 | 187,221,840 | ||||
PepsiCo, Inc.
|
1,097,822 | 162,807,003 | ||||
401,338,240 | ||||||
BIOTECHNOLOGY — 2.1% | ||||||
AbbVie, Inc.
|
3,317,435 | 355,463,160 | ||||
BUILDING PRODUCTS — 0.9% | ||||||
A.O. Smith Corp.
|
1,861,773 | 102,062,396 | ||||
Carrier Global Corp.
|
1,557,524 | 58,749,805 | ||||
160,812,201 | ||||||
CAPITAL MARKETS — 4.7% | ||||||
Eaton Vance Corp.
|
2,761,660 | 187,599,564 | ||||
FactSet Research Systems, Inc.
|
145,376 | 48,337,520 | ||||
Franklin Resources, Inc.
|
11,866,999 | 296,556,305 | ||||
S&P Global, Inc.
|
114,364 | 37,594,878 | ||||
SEI Investments Co.
|
1,377,278 | 79,152,166 | ||||
T Rowe Price Group, Inc.
|
984,303 | 149,013,631 | ||||
798,254,064 |
Security Description | Shares | Value | ||||
CHEMICALS — 4.3% | ||||||
Air Products & Chemicals, Inc.
|
317,822 | $ 86,835,327 | ||||
Albemarle Corp. (a)
|
928,217 | 136,930,572 | ||||
Ecolab, Inc.
|
238,456 | 51,592,340 | ||||
HB Fuller Co. (a)
|
1,487,146 | 77,153,134 | ||||
Linde PLC (c)
|
358,527 | 94,475,450 | ||||
PPG Industries, Inc.
|
684,152 | 98,668,401 | ||||
RPM International, Inc.
|
1,062,119 | 96,419,163 | ||||
Sherwin-Williams Co.
|
58,418 | 42,931,972 | ||||
Stepan Co.
|
491,330 | 58,625,496 | ||||
743,631,855 | ||||||
COMMERCIAL SERVICES & SUPPLIES — 1.9% | ||||||
ABM Industries, Inc.
|
2,938,244 | 111,183,153 | ||||
Brady Corp. Class A
|
1,865,440 | 98,532,541 | ||||
Cintas Corp.
|
117,642 | 41,581,741 | ||||
MSA Safety, Inc. (a)
|
463,825 | 69,290,817 | ||||
320,588,252 | ||||||
CONTAINERS & PACKAGING — 2.9% | ||||||
Amcor PLC
|
19,703,044 | 231,904,828 | ||||
AptarGroup, Inc.
|
558,061 | 76,392,970 | ||||
Sonoco Products Co.
|
3,286,395 | 194,718,904 | ||||
503,016,702 | ||||||
DISTRIBUTORS — 1.0% | ||||||
Genuine Parts Co.
|
1,745,288 | 175,279,274 | ||||
DIVERSIFIED TELECOMMUNICATION SERVICES — 2.3% | ||||||
AT&T, Inc.
|
13,616,137 | 391,600,100 | ||||
ELECTRIC UTILITIES — 1.4% | ||||||
Eversource Energy
|
1,533,831 | 132,691,720 | ||||
NextEra Energy, Inc.
|
1,382,609 | 106,668,284 | ||||
239,360,004 | ||||||
ELECTRICAL EQUIPMENT — 2.2% | ||||||
Emerson Electric Co.
|
2,261,738 | 181,775,883 | ||||
nVent Electric PLC (b)
|
8,629,800 | 200,988,042 | ||||
382,763,925 | ||||||
EQUITY REAL ESTATE INVESTMENT TRUSTS (REITS) — 7.0% | ||||||
Essex Property Trust, Inc. REIT
|
1,057,302 | 251,024,641 | ||||
Federal Realty Investment Trust REIT (a)
(b)
|
3,907,227 | 332,583,162 |
Security Description | Shares | Value | ||||
National Retail Properties, Inc. REIT (b)
|
8,890,420 | $ 363,795,986 | ||||
Realty Income Corp. REIT
|
3,950,510 | 245,603,207 | ||||
1,193,006,996 | ||||||
FOOD & STAPLES RETAILING — 3.3% | ||||||
Casey's General Stores, Inc.
|
205,191 | 36,651,216 | ||||
Sysco Corp.
|
2,317,951 | 172,131,041 | ||||
Walmart, Inc.
|
557,224 | 80,323,840 | ||||
Walgreens Boots Alliance, Inc.
|
7,105,719 | 283,376,074 | ||||
572,482,171 | ||||||
FOOD PRODUCTS — 3.3% | ||||||
Archer-Daniels-Midland Co.
|
3,100,531 | 156,297,768 | ||||
Hormel Foods Corp. (a)
|
1,990,810 | 92,791,654 | ||||
J.M. Smucker Co. (a)
|
1,400,451 | 161,892,135 | ||||
Lancaster Colony Corp.
|
444,288 | 81,629,034 | ||||
McCormick & Co., Inc.
|
675,343 | 64,562,791 | ||||
557,173,382 | ||||||
GAS UTILITIES — 5.4% | ||||||
Atmos Energy Corp.
|
1,278,820 | 122,037,793 | ||||
National Fuel Gas Co. (a)
|
4,213,292 | 173,292,700 | ||||
New Jersey Resources Corp. (a)
|
4,130,132 | 146,826,192 | ||||
Northwest Natural Holding Co. (a) (b)
|
1,531,481 | 70,432,811 | ||||
South Jersey Industries, Inc. (a) (b)
|
9,426,731 | 203,146,053 | ||||
UGI Corp.
|
5,795,024 | 202,594,039 | ||||
918,329,588 | ||||||
HEALTH CARE EQUIPMENT & SUPPLIES — 1.6% | ||||||
Abbott Laboratories
|
637,312 | 69,779,291 | ||||
Becton Dickinson and Co.
|
293,420 | 73,419,553 | ||||
Medtronic PLC
|
1,040,365 | 121,868,356 | ||||
West Pharmaceutical Services, Inc.
|
42,868 | 12,144,933 | ||||
277,212,133 | ||||||
HEALTH CARE PROVIDERS & SERVICES — 1.4% | ||||||
Cardinal Health, Inc.
|
4,356,338 | 233,325,463 | ||||
HOTELS, RESTAURANTS & LEISURE — 0.7% | ||||||
McDonald's Corp.
|
533,690 | 114,519,200 | ||||
HOUSEHOLD DURABLES — 1.2% | ||||||
Leggett & Platt, Inc.
|
4,540,569 | 201,147,207 |
Security Description | Shares | Value | ||||
HOUSEHOLD PRODUCTS — 3.2% | ||||||
Church & Dwight Co., Inc.
|
578,729 | $ 50,482,531 | ||||
Clorox Co. (a)
|
519,466 | 104,890,575 | ||||
Colgate-Palmolive Co.
|
1,492,896 | 127,657,537 | ||||
Kimberly-Clark Corp.
|
1,099,517 | 148,247,877 | ||||
Procter & Gamble Co.
|
829,829 | 115,462,407 | ||||
546,740,927 | ||||||
INDUSTRIAL CONGLOMERATES — 1.9% | ||||||
3M Co.
|
1,122,432 | 196,189,889 | ||||
Carlisle Cos., Inc.
|
676,528 | 105,660,143 | ||||
Roper Technologies, Inc.
|
62,859 | 27,097,887 | ||||
328,947,919 | ||||||
INSURANCE — 5.7% | ||||||
Aflac, Inc.
|
4,226,560 | 187,955,123 | ||||
Brown & Brown, Inc.
|
908,300 | 43,062,503 | ||||
Chubb, Ltd.
|
1,081,240 | 166,424,461 | ||||
Cincinnati Financial Corp.
|
2,064,797 | 180,401,314 | ||||
Old Republic International Corp.
|
14,925,138 | 294,174,470 | ||||
RenaissanceRe Holdings, Ltd.
|
240,244 | 39,837,260 | ||||
RLI Corp. (a)
|
636,727 | 66,315,117 | ||||
978,170,248 | ||||||
IT SERVICES — 2.7% | ||||||
Automatic Data Processing, Inc.
|
908,062 | 160,000,525 | ||||
International Business Machines Corp.
|
2,398,565 | 301,931,362 | ||||
461,931,887 | ||||||
LEISURE EQUIPMENT & PRODUCTS — 0.8% | ||||||
Polaris, Inc.
|
1,488,900 | 141,862,392 | ||||
MACHINERY — 6.0% | ||||||
Caterpillar, Inc.
|
850,733 | 154,850,421 | ||||
Donaldson Co., Inc.
|
1,814,141 | 101,374,199 | ||||
Dover Corp.
|
816,100 | 103,032,625 | ||||
Franklin Electric Co., Inc.
|
865,231 | 59,882,638 | ||||
Graco, Inc.
|
924,016 | 66,852,558 | ||||
Illinois Tool Works, Inc.
|
592,818 | 120,863,734 | ||||
Lincoln Electric Holdings, Inc.
|
1,090,381 | 126,756,791 | ||||
Nordson Corp.
|
203,416 | 40,876,445 | ||||
Otis Worldwide Corp.
|
1,048,744 | 70,842,657 | ||||
Pentair PLC
|
1,658,952 | 88,073,762 |
Security Description | Shares | Value | ||||
Stanley Black & Decker, Inc.
|
503,524 | $ 89,909,245 | ||||
1,023,315,075 | ||||||
MEDIA — 0.6% | ||||||
John Wiley & Sons, Inc. Class A (a)
|
2,292,808 | 104,689,613 | ||||
METALS & MINING — 1.2% | ||||||
Nucor Corp.
|
3,712,761 | 197,481,758 | ||||
MULTI-UTILITIES — 3.4% | ||||||
Black Hills Corp. (b)
|
3,137,825 | 192,819,346 | ||||
Consolidated Edison, Inc.
|
2,502,641 | 180,865,865 | ||||
MDU Resources Group, Inc.
|
7,732,367 | 203,670,547 | ||||
577,355,758 | ||||||
MULTILINE RETAIL — 0.6% | ||||||
Target Corp.
|
559,863 | 98,832,615 | ||||
OIL, GAS & CONSUMABLE FUELS — 6.2% | ||||||
Chevron Corp.
|
5,127,478 | 433,015,517 | ||||
Exxon Mobil Corp.
|
15,407,461 | 635,095,543 | ||||
1,068,111,060 | ||||||
PHARMACEUTICALS — 0.9% | ||||||
Johnson & Johnson
|
970,096 | 152,673,709 | ||||
SPECIALTY RETAIL — 0.4% | ||||||
Lowe's Cos., Inc.
|
436,453 | 70,055,071 | ||||
TEXTILES, APPAREL & LUXURY GOODS — 1.0% | ||||||
VF Corp.
|
1,935,871 | 165,342,742 | ||||
TRADING COMPANIES & DISTRIBUTORS — 1.3% | ||||||
Fastenal Co.
|
2,558,914 | 124,951,771 | ||||
W.W. Grainger, Inc.
|
246,688 | 100,732,578 | ||||
225,684,349 | ||||||
WATER UTILITIES — 2.0% | ||||||
American States Water Co.
|
1,171,622 | 93,155,665 | ||||
California Water Service Group
|
1,916,586 | 103,553,142 | ||||
Essential Utilities, Inc. (a)
|
2,906,909 | 137,467,726 | ||||
334,176,533 |
Security Description | Shares | Value | ||||
WIRELESS TELECOMMUNICATION SERVICES — 0.6% | ||||||
Telephone & Data Systems, Inc. (b)
|
6,006,342 | $ 111,537,771 | ||||
TOTAL COMMON STOCKS (Cost
$15,626,018,489)
|
17,079,703,506 | |||||
SHORT-TERM INVESTMENTS — 0.2% | ||||||
State Street Institutional Liquid Reserves Fund,
Premier Class 0.10% (d) (e)
|
11,535,876 | 11,538,183 | ||||
State Street Navigator Securities Lending
Portfolio II (f) (g)
|
26,776,728 | 26,776,728 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost
$38,314,911)
|
38,314,911 | |||||
TOTAL INVESTMENTS — 100.0% (Cost
$15,664,333,400)
|
17,118,018,417 | |||||
OTHER ASSETS IN EXCESS OF LIABILITIES — 0.0%
(h)
|
6,625,913 | |||||
NET ASSETS — 100.0%
|
$17,124,644,330 |
(a) | All or a portion of the shares of the security are on loan at December 31, 2020. |
(b) | These securities are affiliated investments as a result of the Fund owning 5% or more of the entity’s outstanding shares. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(c) | Non-income producing security. |
(d) | The Fund invested in certain money market funds managed by SSGA Funds Management, Inc. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(e) | The rate shown is the annualized seven-day yield at December 31, 2020. |
(f) | The Fund invested in an affiliated entity. Amounts related to these transactions during the period ended December 31, 2020 are shown in the Affiliate Table below. |
(g) | Investment of cash collateral for securities loaned. |
(h) | Amount is less than 0.05% of net assets. |
REIT | Real Estate Investment Trust |
Description | Level
1 – Quoted Prices |
Level
2 – Other Significant Observable Inputs |
Level
3 – Significant Unobservable Inputs |
Total | ||||
ASSETS: | ||||||||
INVESTMENTS: | ||||||||
Common Stocks
|
$17,079,703,506 | $— | $— | $17,079,703,506 | ||||
Short-Term Investments
|
38,314,911 | — | — | 38,314,911 | ||||
TOTAL INVESTMENTS
|
$ 17,118,018,417 | $— | $— | $ 17,118,018,417 |
Number
of Shares Held at 6/30/20 |
Value
at 6/30/20 |
Cost
of Purchases |
Proceeds
from Shares Sold |
Realized
Gain (Loss) |
Change
in Unrealized Appreciation/ Depreciation(a) |
Number
of Shares Held at 12/31/20 |
Value
at 12/31/20 |
Dividend
Income | |||||||||
ABM Industries, Inc.
|
3,496,319 | $ 126,916,380 | $ 22,491,052 | $ 42,416,797 | $ (501,145) | $ —* | — | $ —* | $ 1,171,920 | ||||||||
Bank OZK
|
11,770,632 | 276,256,733 | 48,640,041 | 174,877,054 | (42,827,236) | 97,496,589 | 6,545,861 | 204,689,073 | 5,696,509 | ||||||||
Black Hills Corp.
|
2,026,321 | 114,811,348 | 80,273,695 | 14,945,271 | (259,999) | 12,939,573 | 3,137,825 | 192,819,346 | 3,366,687 | ||||||||
Cullen/Frost Bankers, Inc.
|
3,189,184 | 238,263,937 | 48,284,918 | 76,812,672 | (3,994,943) | —* | — | —* | 3,789,592 | ||||||||
Federal Realty Investment Trust
|
3,029,246 | 258,122,052 | 80,909,359 | 18,142,751 | 1,288,900 | 10,405,602 | 3,907,227 | 332,583,162 | 7,574,914 | ||||||||
HB Fuller Co.
|
2,718,062 | 121,225,565 | 19,021,868 | 74,596,360 | 9,857,982 | —* | — | —* | 689,066 | ||||||||
John Wiley & Sons, Inc.
|
2,676,536 | 104,384,904 | 26,336,574 | 36,617,917 | (20,259,709) | —* | — | —* | 2,742,896 | ||||||||
Leggett & Platt, Inc.
|
7,856,841 | 276,167,961 | 52,720,060 | 189,063,220 | 16,272,306 | —* | — | —* | 4,247,974 | ||||||||
National Fuel Gas Co.
|
4,312,353 | 180,816,961 | 51,431,657 | 54,962,850 | (5,190,632) | —* | — | —* | 4,057,180 | ||||||||
National Retail Properties, Inc.
|
8,332,186 | 295,625,959 | 62,302,081 | 43,095,988 | (10,711,470) | 59,675,404 | 8,890,420 | 363,795,986 | 8,928,589 | ||||||||
New Jersey Resources Corp.
|
4,313,668 | 140,841,260 | 37,412,164 | 40,789,208 | (16,715,474) | —* | — | —* | 2,976,888 | ||||||||
Northwest Natural Holding Co.
|
1,853,023 | 103,380,153 | 17,351,689 | 32,572,754 | (14,084,945) | (3,641,332) | 1,531,481 | 70,432,811 | 1,752,253 | ||||||||
nVent Electric PLC
|
9,090,838 | 170,271,396 | 46,819,232 | 54,426,575 | (13,917,408) | 52,241,397 | 8,629,800 | 200,988,042 | 2,826,516 | ||||||||
People's United Financial, Inc.
|
21,697,953 | 251,045,316 | 128,803,564 | 19,600,253 | 522,661 | 49,046,045 | 31,695,076 | 409,817,333 | 8,941,943 | ||||||||
Polaris, Inc.
|
3,164,816 | 292,903,721 | 47,823,767 | 221,986,688 | 58,781,926 | —* | — | —* | 1,762,734 | ||||||||
South Jersey Industries, Inc.
|
6,542,373 | 163,493,901 | 71,054,626 | 11,158,697 | (477,338) | (19,766,439) | 9,426,731 | 203,146,053 | 5,005,405 | ||||||||
State Street Institutional Liquid Reserves Fund,
Premier Class
|
16,175,997 | 16,182,467 | 448,668,513 | 453,309,133 | 8,608 | (12,272) | 11,535,876 | 11,538,183 | 23,455 | ||||||||
State Street Navigator Securities Lending
Portfolio II
|
160,240,114 | 160,240,114 | 810,582,217 | 944,045,603 | — | — | 26,776,728 | 26,776,728 | 94,013 | ||||||||
Telephone & Data Systems, Inc.
|
7,119,547 | 141,536,594 | 24,669,300 | 45,144,092 | (24,714,574) | 15,190,543 | 6,006,342 | 111,537,771 | 2,129,357 | ||||||||
United Bankshares, Inc.
|
6,311,500 | 174,576,090 | 32,480,864 | 94,287,900 | (36,282,792) | —* | — | —* | 3,710,417 | ||||||||
Total
|
$3,607,062,812 | $2,158,077,241 | $2,642,851,783 | $(103,205,282) | $273,575,110 | $2,128,124,488 | $71,488,308 |
(a) | Does not include change in unrealized appreciation and depreciation from investments that are no longer affiliates at period ended December 31, 2020. |
* | As of December 31, 2020, no longer an affiliate. |
SPDR Dow Jones REIT ETF | SPDR S&P Biotech ETF | SPDR S&P Dividend ETF | |||
ASSETS | |||||
Investments in unaffiliated issuers, at
value*
|
$1,365,887,514 | $ 6,311,735,280 | $14,989,893,929 | ||
Investments in affiliated issuers, at value
|
19,297,349 | 1,676,913,825 | 2,128,124,488 | ||
Total Investments
|
1,385,184,863 | 7,988,649,105 | 17,118,018,417 | ||
Cash
|
261,792 | 521,446 | — | ||
Receivable for fund shares sold
|
4,519 | — | — | ||
Dividends receivable — unaffiliated issuers
|
6,512,213 | — | 38,451,181 | ||
Dividends receivable — affiliated issuers
|
119 | 607 | 4,919 | ||
Securities lending income receivable —
unaffiliated issuers
|
3,724 | 112,626 | 10,487 | ||
Securities lending income receivable — affiliated
issuers
|
17,703 | 3,099,584 | 7,809 | ||
TOTAL ASSETS
|
1,391,984,933 | 7,992,383,368 | 17,156,492,813 | ||
LIABILITIES | |||||
Payable upon return of securities loaned
|
17,113,729 | 1,086,364,528 | 26,776,728 | ||
Payable for investments purchased
|
1,760,623 | 521,447 | — | ||
Payable for fund shares repurchased
|
— | 3,435 | 3,997 | ||
Advisory fee payable
|
287,581 | 2,159,415 | 5,050,577 | ||
Trustees’ fees and expenses payable
|
4,198 | — | 17,181 | ||
TOTAL LIABILITIES
|
19,166,131 | 1,089,048,825 | 31,848,483 | ||
NET ASSETS
|
$1,372,818,802 | $ 6,903,334,543 | $17,124,644,330 | ||
NET ASSETS CONSIST OF: | |||||
Paid-in Capital
|
$1,725,853,171 | $10,158,869,475 | $17,108,270,061 | ||
Total distributable earnings (loss)
|
(353,034,369) | (3,255,534,932) | 16,374,269 | ||
NET ASSETS
|
$1,372,818,802 | $ 6,903,334,543 | $17,124,644,330 | ||
NET ASSET VALUE PER SHARE | |||||
Net asset value per share
|
$ 86.71 | $ 140.81 | $ 105.93 | ||
Shares outstanding (unlimited amount authorized,
$0.01 par value)
|
15,831,617 | 49,025,000 | 161,653,658 | ||
COST OF INVESTMENTS: | |||||
Investments in unaffiliated issuers
|
$1,515,939,143 | $ 6,296,663,099 | $13,372,086,827 | ||
Investments in affiliated issuers
|
19,297,349 | 1,905,294,850 | 2,292,246,573 | ||
Total cost of investments
|
$1,535,236,492 | $ 8,201,957,949 | $15,664,333,400 | ||
* Includes investments in securities on loan, at
value
|
$ 19,596,282 | $ 1,531,172,242 | $ 120,038,519 |
SPDR Dow Jones REIT ETF | SPDR S&P Biotech ETF | SPDR S&P Dividend ETF | |||
INVESTMENT INCOME | |||||
Dividend income — unaffiliated issuers
|
$ 34,778,630 | $ 3,266,036 | $ 222,174,561 | ||
Dividend income — affiliated issuers
|
943 | 5,000 | 71,394,295 | ||
Dividend income — non-cash transactions
|
2,168,875 | — | — | ||
Unaffiliated securities lending income
|
19,889 | 1,219,663 | 68,426 | ||
Affiliated securities lending income
|
113,401 | 18,189,352 | 94,013 | ||
TOTAL INVESTMENT INCOME (LOSS)
|
37,081,738 | 22,680,051 | 293,731,295 | ||
EXPENSES | |||||
Advisory fee
|
1,623,630 | 10,674,662 | 27,933,950 | ||
Trustees’ fees and expenses
|
15,088 | 41,081 | 140,561 | ||
TOTAL EXPENSES
|
1,638,718 | 10,715,743 | 28,074,511 | ||
NET INVESTMENT INCOME (LOSS)
|
$ 35,443,020 | $ 11,964,308 | $ 265,656,784 | ||
REALIZED AND UNREALIZED GAIN (LOSS) | |||||
Net realized gain (loss) on: | |||||
Investments — unaffiliated issuers
|
(16,601,635) | (399,040,878) | (144,345,061) | ||
Investments — affiliated issuers
|
(1,085) | 77,580,268 | (209,238,841) | ||
In-kind redemptions — unaffiliated issuers
|
17,628,857 | 1,743,182,893 | 686,362,119 | ||
In-kind redemptions — affiliated issuers
|
— | 5,817,277 | 106,033,559 | ||
Net realized gain (loss)
|
1,026,137 | 1,427,539,560 | 438,811,776 | ||
Net change in unrealized appreciation/depreciation on: | |||||
Investments — unaffiliated issuers
|
129,531,878 | 271,412,502 | 1,706,640,487 | ||
Investment — affiliated issuers
|
— | (221,257,020) | 193,636,651 | ||
Net change in unrealized
appreciation/depreciation
|
129,531,878 | 50,155,482 | 1,900,277,138 | ||
NET REALIZED AND UNREALIZED GAIN (LOSS)
|
130,558,015 | 1,477,695,042 | 2,339,088,914 | ||
NET INCREASE (DECREASE) IN NET ASSETS FROM
OPERATIONS
|
$166,001,035 | $1,489,659,350 | $2,604,745,698 |
SPDR Dow Jones REIT ETF | |||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 | ||
INCREASE (DECREASE) IN NET ASSETS FROM OPERATIONS: | |||
Net investment income (loss)
|
$ 35,443,020 | $ 58,164,383 | |
Net realized gain (loss)
|
1,026,137 | (33,015,910) | |
Net change in unrealized
appreciation/depreciation
|
129,531,878 | (401,412,206) | |
Net increase (decrease) in net assets resulting
from operations
|
166,001,035 | (376,263,733) | |
Net equalization credits and charges
|
1,498,112 | (2,277,335) | |
Distributions to shareholders
|
(30,726,291) | (76,076,130) | |
FROM BENEFICIAL INTEREST TRANSACTIONS: | |||
Proceeds from shares sold
|
147,494,060 | 491,798,632 | |
Cost of shares redeemed
|
(263,112,678) | (1,219,091,891) | |
Net income equalization
|
(1,498,112) | 2,277,335 | |
Net increase (decrease) in net assets from
beneficial interest transactions
|
(117,116,730) | (725,015,924) | |
Net increase (decrease) in net assets during the
period
|
19,656,126 | (1,179,633,122) | |
Net assets at beginning of period
|
1,353,162,676 | 2,532,795,798 | |
NET ASSETS AT END OF PERIOD
|
$1,372,818,802 | $ 1,353,162,676 | |
SHARES OF BENEFICIAL INTEREST: | |||
Shares sold
|
1,750,000 | 5,300,000 | |
Shares redeemed
|
(3,250,000) | (13,600,000) | |
Net increase (decrease) from share
transactions
|
(1,500,000) | (8,300,000) |
SPDR S&P Biotech ETF | |||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 | ||
INCREASE (DECREASE) IN NET ASSETS FROM OPERATIONS: | |||
Net investment income (loss)
|
$ 11,964,308 | $ 296,157 | |
Net realized gain (loss)
|
1,427,539,560 | 570,946,754 | |
Net change in unrealized
appreciation/depreciation
|
50,155,482 | 477,966,904 | |
Net increase (decrease) in net assets resulting
from operations
|
1,489,659,350 | 1,049,209,815 | |
Net equalization credits and charges
|
(19,785) | 35,202 | |
Distributions to shareholders
|
(13,236,987) | (928,142) | |
FROM BENEFICIAL INTEREST TRANSACTIONS: | |||
Proceeds from shares sold
|
12,169,324,892 | 18,679,802,929 | |
Cost of shares redeemed
|
(12,145,060,032) | (18,738,305,166) | |
Net income equalization
|
19,785 | (35,202) | |
Net increase (decrease) in net assets from
beneficial interest transactions
|
24,284,645 | (58,537,439) | |
Net increase (decrease) in net assets during the
period
|
1,500,687,223 | 989,779,436 | |
Net assets at beginning of period
|
5,402,647,320 | 4,412,867,884 | |
NET ASSETS AT END OF PERIOD
|
$ 6,903,334,543 | $ 5,402,647,320 | |
SHARES OF BENEFICIAL INTEREST: | |||
Shares sold
|
98,025,000 | 208,575,000 | |
Shares redeemed
|
(97,225,000) | (210,600,000) | |
Net increase (decrease) from share
transactions
|
800,000 | (2,025,000) |
SPDR S&P Dividend ETF | |||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 | ||
INCREASE (DECREASE) IN NET ASSETS FROM OPERATIONS: | |||
Net investment income (loss)
|
$ 265,656,784 | $ 515,368,413 | |
Net realized gain (loss)
|
438,811,776 | 1,239,710,443 | |
Net change in unrealized
appreciation/depreciation
|
1,900,277,138 | (3,188,460,306) | |
Net increase (decrease) in net assets resulting
from operations
|
2,604,745,698 | (1,433,381,450) | |
Net equalization credits and charges
|
(1,769,466) | (7,547,203) | |
Distributions to shareholders
|
(270,680,097) | (509,825,739) | |
FROM BENEFICIAL INTEREST TRANSACTIONS: | |||
Proceeds from shares sold
|
3,259,919,682 | 6,522,295,627 | |
Cost of shares redeemed
|
(3,667,206,787) | (8,079,251,362) | |
Net income equalization
|
1,769,466 | 7,547,203 | |
Net increase (decrease) in net assets from
beneficial interest transactions
|
(405,517,639) | (1,549,408,532) | |
Net increase (decrease) in net assets during the
period
|
1,926,778,496 | (3,500,162,924) | |
Net assets at beginning of period
|
15,197,865,834 | 18,698,028,758 | |
NET ASSETS AT END OF PERIOD
|
$17,124,644,330 | $15,197,865,834 | |
SHARES OF BENEFICIAL INTEREST: | |||
Shares sold
|
34,000,000 | 65,550,000 | |
Shares redeemed
|
(38,900,000) | (84,200,000) | |
Net increase (decrease) from share
transactions
|
(4,900,000) | (18,650,000) |
SPDR Dow Jones REIT ETF | |||||||||||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 |
Year
Ended 6/30/19 |
Year
Ended 6/30/18 |
Year
Ended 6/30/17 |
Year
Ended 6/30/16 | ||||||
Net asset value, beginning of period
|
$ 78.07 | $ 98.82 | $ 93.80 | $ 92.99 | $ 99.44 | $ 84.38 | |||||
Income (loss) from investment operations: | |||||||||||
Net investment income (loss) (a)
|
2.24 | 2.50 | 2.74 | 2.47 | 1.62 | 2.83 | |||||
Net realized and unrealized gain (loss) (b)
|
8.25 | (19.84) | 5.92 | 1.20 | (4.28) | 15.72 | |||||
Total from investment operations
|
10.49 | (17.34) | 8.66 | 3.67 | (2.66) | 18.55 | |||||
Net equalization credits and charges
|
0.09 | (0.10) | 0.01 | (0.04) | (0.09) | 0.03 | |||||
Distributions to shareholders from: | |||||||||||
Net investment income
|
(1.94) | (3.31) | (3.65) | (2.82) | (3.70) | (3.52) | |||||
Net asset value, end of period
|
$ 86.71 | $ 78.07 | $ 98.82 | $ 93.80 | $ 92.99 | $ 99.44 | |||||
Total return (c)
|
13.72% | (18.04)% | 9.58% | 4.03% | (2.73)% | 22.43% | |||||
Ratios and Supplemental Data: | |||||||||||
Net assets, end of period (in 000s)
|
$1,372,819 | $1,353,163 | $2,532,796 | $2,563,630 | $3,015,901 | $3,816,521 | |||||
Ratios to average net assets: | |||||||||||
Total expenses
|
0.25%(d) | 0.25% | 0.25% | 0.25% | 0.25% | 0.25% | |||||
Net investment income (loss)
|
5.46%(d) | 2.61% | 2.89% | 2.72% | 1.71% | 3.14% | |||||
Portfolio turnover rate (e)
|
4%(f) | 17% | 9% | 6% | 9% | 10% |
(a) | Per share numbers have been calculated using average shares outstanding, which more appropriately presents the per share data for the period. |
(b) | Amounts shown in this caption for a share outstanding may not accord with the change in aggregate gains and losses in securities for the fiscal period because of the timing of sales and repurchases of Fund shares in relation to fluctuating market values for the Fund. |
(c) | Total return is calculated assuming a purchase of shares at net asset value on the first day and a sale at net asset value on the last day of each period reported. Distributions are assumed, for the purpose of this calculation, to be reinvested at net asset value per share on the respective payment dates of each distribution. Total returns for periods of less than one year are not annualized. Broker commission charges are not included in this calculation. |
(d) | Annualized. |
(e) | Portfolio turnover rate excludes securities received or delivered from in-kind processing of creations or redemptions. |
(f) | Not annualized. |
SPDR S&P Biotech ETF | |||||||||||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 |
Year
Ended 6/30/19 |
Year
Ended 6/30/18 |
Year
Ended 6/30/17 |
Year
Ended 6/30/16(a) | ||||||
Net asset value, beginning of period
|
$ 112.03 | $ 87.82 | $ 95.23 | $ 77.15 | $ 54.16 | $ 84.11 | |||||
Income (loss) from investment operations: | |||||||||||
Net investment income (loss) (b)
|
0.24 | 0.01 | 0.04 | 0.20 | 0.20 | 0.29 | |||||
Net realized and unrealized gain (loss) (c)
|
28.80 | 24.22 | (7.37) | 18.06 | 22.97 | (29.93) | |||||
Total from investment operations
|
29.04 | 24.23 | (7.33) | 18.26 | 23.17 | (29.64) | |||||
Net equalization credits and charges (b)
|
(0.00)(d) | 0.00(d) | 0.00(d) | 0.01 | (0.00)(d) | (0.01) | |||||
Distributions to shareholders from: | |||||||||||
Net investment income
|
(0.26) | (0.02) | (0.08) | (0.19) | (0.18) | (0.30) | |||||
Net asset value, end of period
|
$ 140.81 | $ 112.03 | $ 87.82 | $ 95.23 | $ 77.15 | $ 54.16 | |||||
Total return (e)
|
25.95% | 27.59% | (7.70)% | 23.69% | 42.80% | (35.30)% | |||||
Ratios and Supplemental Data: | |||||||||||
Net assets, end of period (in 000s)
|
$6,903,335 | $5,402,647 | $4,412,868 | $5,232,982 | $3,548,969 | $1,873,833 | |||||
Ratios to average net assets: | |||||||||||
Total expenses
|
0.35%(f) | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | |||||
Net investment income (loss)
|
0.39%(f) | 0.01% | 0.05% | 0.23% | 0.30% | 0.45% | |||||
Portfolio turnover rate (g)
|
37%(h) | 66% | 45% | 62% | 59% | 75% |
(a) | On September 8, 2015, the SPDR S&P Biotech ETF underwent a 3-for-1 share split. The per share data presented here have been retroactively adjusted to reflect this split. |
(b) | Per share numbers have been calculated using average shares outstanding, which more appropriately presents the per share data for the period. |
(c) | Amounts shown in this caption for a share outstanding may not accord with the change in aggregate gains and losses in securities for the fiscal period because of the timing of sales and repurchases of Fund shares in relation to fluctuating market values for the Fund. |
(d) | Amount is less than $0.005 per share. |
(e) | Total return is calculated assuming a purchase of shares at net asset value on the first day and a sale at net asset value on the last day of each period reported. Distributions are assumed, for the purpose of this calculation, to be reinvested at net asset value per share on the respective payment dates of each distribution. Total returns for periods of less than one year are not annualized. Broker commission charges are not included in this calculation. |
(f) | Annualized. |
(g) | Portfolio turnover rate excludes securities received or delivered from in-kind processing of creations or redemptions. |
(h) | Not annualized. |
SPDR S&P Dividend ETF | |||||||||||
Six
Months Ended 12/31/20 (Unaudited) |
Year
Ended 6/30/20 |
Year
Ended 6/30/19 |
Year
Ended 6/30/18 |
Year
Ended 6/30/17 |
Year
Ended 6/30/16 | ||||||
Net asset value, beginning of period
|
$ 91.25 | $ 100.96 | $ 92.65 | $ 88.93 | $ 83.91 | $ 76.23 | |||||
Income (loss) from investment operations: | |||||||||||
Net investment income (loss) (a)
|
1.63 | 2.84 | 2.41 | 2.31 | 1.81 | 2.01 | |||||
Net realized and unrealized gain (loss) (b)
|
14.73 | (9.68) | 8.30 | 6.10 | 6.01 | 10.29 | |||||
Total from investment operations
|
16.36 | (6.84) | 10.71 | 8.41 | 7.82 | 12.30 | |||||
Net equalization credits and charges (a)
|
(0.01) | (0.04) | 0.02 | (0.03) | 0.01 | 0.01 | |||||
Distributions to shareholders from: | |||||||||||
Net investment income
|
(1.67) | (2.83) | (2.42) | (2.33) | (2.22) | (2.02) | |||||
Net realized gains
|
— | — | — | (2.33) | (0.59) | (2.61) | |||||
Total distributions
|
(1.67) | (2.83) | (2.42) | (4.66) | (2.81) | (4.63) | |||||
Net asset value, end of period
|
$ 105.93 | $ 91.25 | $ 100.96 | $ 92.65 | $ 88.93 | $ 83.91 | |||||
Total return (c)
|
18.08% | (6.82)% | 11.76% | 9.44% | 9.46% | 16.94% | |||||
Ratios and Supplemental Data: | |||||||||||
Net assets, end of period (in 000s)
|
$17,124,644 | $15,197,866 | $18,698,029 | $15,351,950 | $15,478,187 | $14,009,561 | |||||
Ratios to average net assets: | |||||||||||
Total expenses
|
0.35%(d) | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | |||||
Net investment income (loss)
|
3.33%(d) | 2.89% | 2.49% | 2.51% | 2.10% | 2.62% | |||||
Portfolio turnover rate (e)
|
11%(f) | 31% | 20% | 24% | 32% | 32% |
(a) | Per share numbers have been calculated using average shares outstanding, which more appropriately presents the per share data for the period. |
(b) | Amounts shown in this caption for a share outstanding may not accord with the change in aggregate gains and losses in securities for the fiscal period because of the timing of sales and repurchases of Fund shares in relation to fluctuating market values for the Fund. |
(c) | Total return is calculated assuming a purchase of shares at net asset value on the first day and a sale at net asset value on the last day of each period reported. Distributions are assumed, for the purpose of this calculation, to be reinvested at net asset value per share on the respective payment dates of each distribution. Total returns for periods of less than one year are not annualized. Broker commission charges are not included in this calculation. |
(d) | Annualized. |
(e) | Portfolio turnover rate excludes securities received or delivered from in-kind processing of creations or redemptions. |
(f) | Not annualized. |
SPDR Dow Jones REIT ETF |
SPDR S&P Biotech ETF |
SPDR S&P Dividend ETF |
SPDR Dow Jones REIT ETF |
SPDR S&P Biotech ETF |
SPDR S&P Dividend ETF |
Annual Rate | |
SPDR Dow Jones REIT ETF
|
0.25% |
SPDR S&P Biotech ETF
|
0.35 |
SPDR S&P Dividend ETF
|
0.35 |
Purchases | Sales | ||
SPDR Dow Jones REIT ETF
|
$ 47,868,359 | $ 44,690,409 | |
SPDR S&P Biotech ETF
|
2,181,366,794 | 2,191,964,839 | |
SPDR S&P Dividend ETF
|
1,863,223,494 | 1,712,870,883 |
In-kind
Contributions |
In-kind
Redemptions |
In-kind
Net Realized Gains/(Losses) | |||
SPDR Dow Jones REIT ETF
|
$ 132,979,617 | $ 248,562,349 | $ 17,628,857 | ||
SPDR S&P Biotech ETF
|
7,875,625,390 | 7,835,760,018 | 1,749,000,170 | ||
SPDR S&P Dividend ETF
|
2,936,427,879 | 3,501,177,005 | 792,395,678 |
Tax
Cost |
Gross
Unrealized Appreciation |
Gross
Unrealized Depreciation |
Net
Unrealized Appreciation (Depreciation) | ||||
SPDR Dow Jones REIT ETF
|
$ 1,541,062,186 | $ 85,529,549 | $241,406,872 | $ (155,877,323) | |||
SPDR S&P Biotech ETF
|
8,213,214,805 | 534,303,779 | 758,869,479 | (224,565,700) | |||
SPDR S&P Dividend ETF
|
15,684,299,813 | 2,048,720,209 | 615,001,605 | 1,433,718,604 |
Fund | Market
Value of Securities on Loan |
Cash
Collateral Received |
Non-Cash
Collateral Received* |
Total
Collateral Received | ||||
SPDR Dow Jones REIT ETF
|
$ 19,596,282 | $ 17,113,729 | $ 2,776,873 | $ 19,890,602 | ||||
SPDR S&P Biotech ETF
|
1,531,172,242 | 1,086,364,528 | 541,755,335 | 1,628,119,863 | ||||
SPDR S&P Dividend ETF
|
120,038,519 | 26,776,728 | 96,106,607 | 122,883,335 |
* | The non-cash collateral includes U.S. Treasuries and U.S. Government Agency securities. |
Remaining Contractual Maturity of the Agreements As of December 31, 2020 | ||||||||||||||
Fund | Securities
Lending Transactions |
Overnight
and Continuous |
<30 Days | Between
30 & 90 Days |
>90 Days | Total
Borrowings |
Gross
Amount of Recognized Liabilities for Securities Lending Transactions | |||||||
SPDR Dow Jones REIT ETF
|
Common Stocks | $ 17,113,729 | $— | $— | $— | $ 17,113,729 | $ 17,113,729 | |||||||
SPDR S&P Biotech ETF
|
Common Stocks | 1,086,364,528 | — | — | — | 1,086,364,528 | 1,086,364,528 | |||||||
SPDR S&P Dividend ETF
|
Common Stocks | 26,776,728 | — | — | — | 26,776,728 | 26,776,728 |
SPDR Dow Jones REIT ETF | SPDR S&P Biotech ETF | SPDR S&P Dividend ETF | |||
Annualized Expense Ratio
|
0.25% | 0.35% | 0.35% | ||
Actual: | |||||
Ending Account Value
|
$1,137.20 | $1,259.50 | $1,180.80 | ||
Expenses Paid During Period(a)
|
1.35 | 1.99 | 1.92 | ||
Hypothetical (assuming a 5% return before expenses): | |||||
Ending Account Value
|
1,023.90 | 1,023.40 | 1,023.40 | ||
Expenses Paid During Period(a)
|
1.28 | 1.79 | 1.79 |
(a) | Expenses are equal to the Fund's annualized net expense ratio multiplied by the average account value of the period, multiplied by 184, then divided by 365. |
• | the Program supported each Fund’s ability to honor redemption requests timely; |
• | the Program supported SSGA FM’s management of each Fund’s liquidity profile, including during periods of market volatility and net redemptions; |
• | no material liquidity issues were identified during the period; |
• | there were no material changes to the Program during the period; |
• | the implementation of the Program was effective to manage each Fund’s liquidity risk; and |
• | the Program operated adequately during the period. |